Mogamulizumab, also known as KW-0761 and bearing the chemical identifier 1159266-37-1, represents a distinct approach to addressing cutaneous T-cell lymphoma (CTCL). This engineered monoclonal antibody selectively https://www.targetmol.com/compound/mogamulizumab